Full Text View
Tabular View
No Study Results Posted
Related Studies
CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study
This study is currently recruiting participants.
Verified by Georgetown University, August 2007
First Received: August 28, 2007   Last Updated: January 27, 2009   History of Changes
Sponsors and Collaborators: Georgetown University
American College of Rheumatology Research and Education Foundation
Information provided by: Georgetown University
ClinicalTrials.gov Identifier: NCT00522002
  Purpose

To explore the hypothesis that leg ulcers are associated with hypercoagulable states, the CLUE study will evaluate patients with connective tissue disease associated leg ulcers, to identify risk factors (especially hypercoagulability and immunologic characteristics), characterize pathogenesis, predict response to therapy, and assess the impact of lower extremity ulcers on quality of life.


Condition
Connective Tissue Diseases
Blood Coagulation Disorders
Leg Ulcers
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Systemic Scleroderma
Mixed Connective Tissue Disease

Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Connective Tissue Disease Leg Ulcer Etiology Study

Resource links provided by NLM:


Further study details as provided by Georgetown University:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 300
Study Start Date: August 2007
Estimated Study Completion Date: August 2010
Detailed Description:

Patients with non-healing leg ulcers who are over 18 years old will be eligible to enter the CLUE study. All eligible patients will be evaluated in both the Georgetown University Rheumatology Clinic and the Georgetown University Comprehensive Wound Healing Center. Since these evaluations are part of our routine care of patients, you need to have health insurance to be evaluated in our clinics.

WHAT DOES THE STUDY INVOLVE?

Enrollment in the CLUE study is voluntary, and will not affect your medical care at Georgetown University Hospital.

The standard evaluation of patients with non-healing leg ulcers evaluated in the Georgetown Division of Rheumatology includes an initial history and physical examination, along with hypercoagulable and autoimmune profiles. If this is your first visit to the rheumatology clinic the initial laboratory testing will require 3.5 tablespoons of blood. We will ask for your permission to review your medical record for previous blood test results so that you do not undergo unnecessary testing. If you agree to participate in the CLUE study we will ask you to sign a consent form, allow us to photograph and measure your ulcers, and complete three brief pain and quality-of-life questionnaires. If you continue to follow-up with the Georgetown Division of Rheumatology we will ask you to repeat these questionnaires at each clinic visit. If you prefer to follow-up elsewhere, we will ask for your permission to telephone you once per year to find out how your leg ulcers are doing.

WHAT TREATMENTS ARE AVAILABLE?

The CLUE Study is not a treatment trial. Treatment of your underlying connective tissue disease and leg ulcers will continue according to standard clinical care, as directed by doctors in the Division of Rheumatology and the Comprehensive Wound Healing Center.

In the future, studies testing new medications in patients with lower extremity ulcers may become available, and you may indicate on the consent form whether you would wish to be contacted regarding these studies.

WILL MY INFORMATION BE SECURE?

Information on CLUE study subjects will be stored on a password protected computer which will be kept in a locked room in the Division of Rheumatology.

Your personal data will not be stored in this database and information will be identifiable only by a CLUE patient number.

WHAT ARE THE COSTS?

The CLUE Study is not a treatment trial. Just like any other doctors visit, you or your insurance will be charged for your initial evaluation and follow-up visits. For more information on arranging an initial consultation in the Georgetown Division of Rheumatology, please call (202) 687-8233 and ask for an investigator to call you about the CLUE study. Before your clinic visit can be scheduled, our staff will request that you have your primary care physician, rheumatologist or wound care specialist fax your previous medical records to our office at (202) 687-8579. If you have had previous scans, arteriograms or X-rays performed, please arrange to collect a copy of the scan and bring it to your appointment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with refractory lower extremity ulcers

Criteria

Inclusion Criteria:

  • Patients with refractory lower extremity ulcers
  • Patients with Rheumatoid arthritis, Systemic Lupus Erythematosus, Systemic Scleroderma, Mixed Connective Tissue Disease or with lesions fulfilling a clinical diagnosis of Livedoid Vasculopathy

Exclusion Criteria:

  • Lower extremity ulcers in the setting of diabetes mellitus
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00522002

Contacts
Contact: Victoria K Shanmugam, MD 202-687-8233 vks4@gunet.georgetown.edu

Locations
United States, District of Columbia
Georgetown University Hospital Recruiting
Washington, District of Columbia, United States, 20007
Contact: Victoria K. Shanmugam, MD     202-687-8233     vks4@gunet.georgetown.edu    
Contact: Thomas R. Cupps, MD     202-687-8233     cuppst@georgetown.edu    
Principal Investigator: Victoria K. Shanmugam, MD            
Sub-Investigator: Christopher E. Attinger, MD            
Sub-Investigator: Thomas R. Cupps, MD            
Sub-Investigator: Virginia D. Steen, MD            
Sub-Investigator: Kara Couch, CNP            
Sponsors and Collaborators
Georgetown University
American College of Rheumatology Research and Education Foundation
Investigators
Principal Investigator: Victoria K. Shanmugam, MD Georgetown University Hospital
Study Chair: Thomas R. Cupps, MD Georgetown University Hospital
  More Information

No publications provided

Responsible Party: Georgetown University Hospital ( Victoria Shanmugam, MD )
Study ID Numbers: IRB 2007-306
Study First Received: August 28, 2007
Last Updated: January 27, 2009
ClinicalTrials.gov Identifier: NCT00522002     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Georgetown University:
Connective tissue diseases
Blood coagulation disorders
Leg ulcers
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Systemic Scleroderma
Mixed Connective Tissue Disease

Study placed in the following topic categories:
Autoimmune Diseases
Skin Diseases
Hematologic Diseases
Lupus
Blood Coagulation Disorders
Ulcer
Joint Diseases
Vascular Diseases
Arthritis, Rheumatoid
Rheumatic Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Sharp Syndrome
Lupus Erythematosus, Systemic
Musculoskeletal Diseases
Mixed Connective Tissue Disease
Arthritis
Connective Tissue Diseases
Scleroderma
Scleroderma, Diffuse
Scleroderma, Systemic
Skin Ulcer
Leg Ulcer

Additional relevant MeSH terms:
Autoimmune Diseases
Skin Diseases
Immune System Diseases
Hematologic Diseases
Blood Coagulation Disorders
Ulcer
Joint Diseases
Vascular Diseases
Arthritis, Rheumatoid
Rheumatic Diseases
Hemostatic Disorders
Pathologic Processes
Hemorrhagic Disorders
Lupus Erythematosus, Systemic
Musculoskeletal Diseases
Mixed Connective Tissue Disease
Arthritis
Connective Tissue Diseases
Scleroderma, Diffuse
Cardiovascular Diseases
Scleroderma, Systemic
Skin Ulcer
Leg Ulcer

ClinicalTrials.gov processed this record on July 06, 2009